Triamterene Hydrochlorothiazide
NDC Package 10544-080-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Triamterene Hydrochlorothiazide is this fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.).Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Marketed by Blenheim Pharmacal, Inc., this product is identified by NDC 10544-080 and is authorized under FDA application ANDA072011.

Identification & Billing

NDC Package Code
10544-080-30
Package Description
30 TABLET in 1 BOTTLE
Product Code
10544-080
11-Digit Billing Format
10544008030
RxNorm Crosswalk
  • RxCUI: 310812 - triamterene 37.5 MG / hydroCHLOROthiazide 25 MG Oral Tablet
  • RxCUI: 310812 - hydrochlorothiazide 25 MG / triamterene 37.5 MG Oral Tablet
  • RxCUI: 310812 - HCTZ 25 MG / triamterene 37.5 MG Oral Tablet
  • RxCUI: 310818 - triamterene 75 MG / hydroCHLOROthiazide 50 MG Oral Tablet
  • RxCUI: 310818 - hydrochlorothiazide 50 MG / triamterene 75 MG Oral Tablet

Clinical Specifications

Proprietary Name
Triamterene Hydrochlorothiazide
Dosage Form
-
Usage Information
This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone.Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.).Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary.

Regulatory & Marketing

Labeler Name
Blenheim Pharmacal, Inc.
FDA Application #
ANDA072011
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-01-2012
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 10544-080-30 identifies a specific commercial package of 30 tablet in 1 bottle of Triamterene Hydrochlorothiazide, labeled by Blenheim Pharmacal, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Blenheim Pharmacal, Inc. on August 01, 2012. The current certification is valid through December 31, 2017.

How is this Blenheim Pharmacal, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 10544008030. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
10544-080-30
11-Digit CMS (5-4-2)
10544-0080-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.